CD274 and neoplasm: Although Tidutamab can facilitate the recruitment of T cells and their binding to carcinoid tumor cells, the correlation of PD-L1 expression and poor treatment outcomes suggests that T cells are inactivated by PD-L1-positive tumor cells.